Novo Nordisk A/S
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity
- Conditions
- Overweight and Obesity
- Interventions
- Drug: placebo (semaglutide)
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 201
- Registration Number
- NCT05132088
- Locations
- 🇯🇵
Naka Kinen Clinic, Ibaraki, Japan
🇯🇵ToCROM Clinic, Tokyo, Japan
🇯🇵Osaka University Hospital, Osaka, Japan
A Research Study Looking at New Protein-based Tablets in Healthy Male Participants
- Conditions
- Healthy VolunteersHigh Blood Cholesterol LevelsType 2 Diabetes
- Interventions
- Drug: NNC0385-0434 BDrug: NNC0385-0434 CDrug: NNC0385-0434 E
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 384
- Registration Number
- NCT05129891
- Locations
- 🇩🇪
Parexel International GmbH, Berlin, Germany
🇨🇦Altasciences Company Inc., Montreal, Quebec, Canada
A Research Study of How a New Medicine NNC0365-3769 (Mim8) Works in the Body of Healthy People
- Conditions
- Healthy Volunteers - Haemophilia A
- Interventions
- Drug: Mim8 B, 10 mg/mLDrug: Mim8 B, 100 mg/mLDrug: Mim8 B, placebo
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 66
- Registration Number
- NCT05127473
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
A Research Study Looking Into Levels of the Medicine NNC0385-0434 in the Body and How Well it is Tolerated in Participants With Impaired Kidney Function Compared to Participants With Normal Kidney Function
- Conditions
- Chronic Kidney Disease
- Interventions
- Drug: NNC0385-0434 A 100 mg
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 60
- Registration Number
- NCT05094934
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
A Research Study Looking at the Effect of Food Intake on How the Medicine NN0385-0434 Behaves in the Body of Healthy Participants
- Conditions
- Healthy VolunteersEstablished Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD RiskElevated Cholesterol
- Interventions
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 73
- Registration Number
- NCT05091073
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)
- Conditions
- Haemophilia A
- Interventions
- Drug: turoctocog alfa pegol (N8-GP)
- First Posted Date
- 2021-10-18
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 36
- Registration Number
- NCT05082116
- Locations
- 🇨🇳
Beijing Children's Hospital，Capital Medical University, Beijing, Beijing, China
🇨🇳Fujian Medical University Union Hospital-Hematology, Fuzhou, Fujian, China
🇨🇳Haemotology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2021-10-06
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 411
- Registration Number
- NCT05069545
- Locations
- 🇧🇪
HUB - Hôpital Erasme, Bruxelles, Belgium
🇧🇪Imeldaziekenhuis - Bonheiden - Department of Endocrinology, Bonheiden, Belgium
🇧🇪Cliniques Universitaires Saint-Luc - Serv Endocrinologie - Diabétologie, Bruxelles, Belgium
Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis
- Conditions
- Obesity
- Interventions
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 407
- Registration Number
- NCT05064735
- Locations
- 🇺🇸
PrimeCare Medical Group, Houston, Texas, United States
🇨🇦Premier Clinical Trial Research Network (PCTRN), Hamilton, Ontario, Canada
🇺🇸Baptist Health System, Montgomery, Alabama, United States
A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors
- Conditions
- Haemophilia AHaemophilia A With Inhibitors
- Interventions
- Drug: NNC0365-3769 (Mim8)
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 281
- Registration Number
- NCT05053139
- Locations
- 🇵🇱
Uniwersytecki Szpital Kliniczny im. J.Mikulicza-Radeckiego, Wroclaw, Dolnoslaskie, Poland
🇵🇱Szpital Uniwersytecki, Oddzial Kliniczny Hematologii, Kraków, Małopolskie, Poland
🇵🇱Uniwersytecki Szpital Dzieciecy, Dzial Krwiolecznictwa, Lublin, Poland
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mLDrug: NNC0480-0389 A 10 mg/mL
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 16
- Registration Number
- NCT05046873
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany